Pixium Sees Way Forward For Its Vision-Restoring Implants In A Tough Market
The company has just two quarters’ of cash remaining, but has also achieved major milestones towards the development and commercialization of its implant that hopes to restore vision in patients with age-related macular degeneration.
You may also be interested in...
Investor Eye: Sofinnova Speaks On Deal Execution, Managing Expertise And what’s In Store For The Future
Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.
Money And Materials Will Allow Medtech To Restore Lost Neuro Functions
Medtech Insight spoke to the CEOs of Blackrock Neurotech and Pixium Vision to find out how their devices can restore lost neurological function and how devices that interface with the brain may shape the future of medicine.
AstraZeneca And Huma On Digital’s Value For Pharma
Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.